CLNN Clene Inc

Clene to Present at Upcoming October Conferences

Clene to Present at Upcoming October Conferences

SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October.

2024 Maxim Healthcare Virtual Summit

Date: October 15-17, 2024

Location: Virtual

Presentation: October 15, 2024, at 2:30 p.m. E.T.

Format: Fireside Presentation and 1x1 meetings

Attendance: Sign up to become an

The ThinkEquity Conference 2024

Dates: October 30, 2024

Location: New York, New York, Mandarin Oriental Hotel

Presentation: October 30, 2024, at 3:30 p.m. E.T.

Format: Presentation and 1x1 meetings

Webcast Link:

About Clene

Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit or follow us on and .

Contacts:

Media Contact

Ignacio Guerrero-Ros, Ph.D., or David Schull

Russo Partners, LLC





(858) 717-2310		Investor Contact

Kevin Gardner

LifeSci Advisors



617-283-2856


EN
09/10/2024

Underlying

CLNNClene Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clene Inc

 PRESS RELEASE
Free
CLNN CLENE INC

Clene Improves Cash Position and Runway by Securing New Debt Facility ...

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan Secures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt Improves cash position enabling Clene to generate the additional data to support the new drug application of CNM-Au8® for ALS via an accelerated regulatory pathwayCarries a 12% interest rate per annum and is secured by all assets of CleneIncludes conversion feature on 65% of the new debt facility at a fixed conversion price of $5.67, a 130% premium to Clene’s closing stock price on the day of ...

December 19, 2024 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

FDA Provides Roadmap for Accelerated Approval Pathway Through Submissi...

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented findingsFDA recommends a follow-up meeting to discuss in more detail the analyses needed to support the accelerated approval pathway Additional NfL biomarker collection and analyses are underway and planned to be completed during the second quarter of 2025Clene is proceeding with its New Dr...

December 10, 2024 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Reports Third Quarter 2024 Financial Results and Recent Operatin...

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutesCash, cash equivalents and marketable securities of $14.6 million as of September 30, 2024Amended debt agreement with Avenue Capital to defer principal payments and extend maturity of facility to second quarter of 2025Completed registered direct offering and concurrent private placements to raise $7.3 million in ...

November 13, 2024 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at Upcoming October Conferences

Clene to Present at Upcoming October Conferences SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October. 2024 Maxim Healthcare Virtual SummitDate: October 15-17, ...

October 9, 2024 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Announces Closing of $7.3 Million Registered Direct Offering and...

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility Investment led by healthcare-focused institutional investor with participation from SymBiosis; founding investor Kensington Capital Holdings; Clene’s Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer and Founder; along with support from several other previously existing shareholders$7.3 million registered direct offering and concurrent private placements priced at market under Nasdaq rulesAmended debt facility with Avenue ...

October 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch